ScholarLens Back to search
2016•Translational Cancer ResearchRequires access

Trimming the fat in non-small cell lung cancer: a new small molecule inhibitor of acetyl-CoA carboxylase to target fatty acid synthesis

Amanda L. Davis, Steven J. Kridel

Open publisher page 1 citations

Abstract

In the October 2016 issue of Nature Medicine , Svensson et al. demonstrate that acetyl-CoA carboxylase 1 (ACC1) is required for non-small cell lung cancer (NSCLC) growth in preclinical models and treatment with an allosteric ACC1 inhibitor, ND-646, suppresses NSCLC through fatty acid synthesis inhibition (1). This study provides answers to questions the cancer metabolism field has asked since the discovery that enzymes within the fatty acid synthesis pathway are overexpressed in cancer (2). Is de novo fatty acid synthesis required for tumors to develop and progress? And can enzymes in the pathway be successfully targeted for therapy?

About this research paper

What this paper is about

In the October 2016 issue of Nature Medicine , Svensson et al. demonstrate that acetyl-CoA carboxylase 1 (ACC1) is required for non-small cell lung cancer (NSCLC) growth in preclinical models and treatment with an allosteric ACC1 inhibitor, ND-646, suppresses NSCLC through fatty acid synthesis inhibition (1). This study provides answers to questions the cancer metabolism field has asked since the discovery that enzymes within the fatty acid synthesis pathway are overexpressed in cancer (2). Is de novo fatty acid synthesis required for tumors to develop and progress? And can enzymes in the pathway be successfully targeted for therapy?

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In the October 2016 issue of Nature Medicine , Svensson et al. demonstrate that acetyl-CoA carboxylase 1 (ACC1) is required for non-small cell lung cancer (NSCLC) growth in preclinical models and treatment with an allosteric ACC1 inhibitor, ND-646, suppresses NSCLC through fatty acid synthesis inhibition (1). This study provides answers to questions the cancer metabolism field has asked since the discovery that enzymes within the fatty acid synthesis pathway are overexpressed in cancer (2). Is de novo fatty acid synthesis required for tumors to develop and progress? And can enzymes in the pathway be successfully targeted for therapy?

Key concepts: Fatty acid synthesis, Acetyl-CoA carboxylase, Fatty acid synthase, Pyruvate carboxylase, Fatty acid metabolism, Enzyme, Fatty acid, Small molecule

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Trimming the fat in non-small cell lung cancer: a new small molecule inhibitor of acetyl-CoA carboxylase to target fatty acid synthesis — Research Paper | ScholarLens